ATWLPPR Peptide (TFA)
ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis[1]. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes[2].
Product Specifications
UNSPSC
12352005
Target
Complement System
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ATWLPPR_Peptide_TFA.html
Purity
99.81
Solubility
H2O : 100 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC(C)C)C(N3[C@@H](CCC3)C(N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)[C@H](C)N.OC(C(F)(F)F)=O
Molecular Formula
C42H62F3N11O11
Molecular Weight
954.00
References & Citations
[1]Starzec A, et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF (165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 2007 Dec;28 (12) :2397-402.|[2]Wang J, et al. The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress. PLoS One. 2015 Nov 10;10 (11) :e0142571.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS7150636 Inquire
Rabbit anti-Escherichia coli O6:H1 (strain CFT073/700928/UPEC) YHBY Polyclonal Antibody
Sign In for Pricing
View Details 
